GleamWall
中文EN

JNJ JOHNSON & JOHNSON

Pharmaceutical Preparations · NYSE · SEC CIK 200406 · Fiscal year ends 01/03

Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.8%
TTM net income YoY-35.9%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR5.9%
Net income 3-yr CAGR-22.5%

Margins

Gross margin67.6%
Operating margin—
Net margin16.2%
FCF margin20.7%
EBITDA margin—

Returns

ROE20.0%
ROA8.2%
ROIC (approx.)—
Asset turnover0.51x

Leverage & solvency

Liabilities / assets58.7%
Debt / equity0.55x
Current ratio1.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.63x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-272026Q22026-06-282026Q12026-03-292025Q4*2025-12-282025Q32025-09-282025Q22025-06-292025Q12025-03-302024Q4*2024-12-29
Income statement
Revenue$25.40B$25.31B$24.06B$24.56B$23.99B$23.74B$21.89B$22.52B
Cost of revenue$8.10B$8.05B$8.11B$7.97B$7.30B$7.63B$7.36B$7.13B
Gross profit$17.30B$17.26B$15.96B$16.60B$16.69B$16.11B$14.54B$15.39B
R&D expense$4.65B$3.65B$3.53B-$10.30B$3.67B$3.52B$3.23B-$10.09B
SG&A expense$6.29B$6.43B$6.03B$6.75B$5.92B$5.89B$5.11B$6.45B
Interest expense$217.00M$281.00M$272.00M$214.00M$245.00M$308.00M$204.00M$137.00M
Pretax income$34.00M$6.75B$5.99B$4.97B$7.49B$6.49B$13.63B$3.89B
Income tax-$176.00M$1.21B$755.00M-$150.00M$2.34B$954.00M$2.63B$456.00M
Net income$210.00M$5.53B$5.24B$5.12B$5.15B$5.54B$11.00B$3.43B
EPS (basic)0.092.302.17—2.142.304.57—
EPS (diluted)0.092.272.14—2.122.294.54—
Dividends declared per share1.341.341.301.301.301.301.241.24
Weighted avg. shares (diluted)2.45B2.44B2.45B—2.43B2.42B2.42B—
Balance sheet
Cash & equivalents$16.91B$20.42B$21.69B$19.71B$18.23B$18.58B$38.47B$24.11B
Short-term investments$318.00M$336.00M$363.00M$393.00M$331.00M$303.00M$307.00M$417.00M
Receivables$18.99B$19.05B$17.72B$17.18B$17.61B$17.85B$16.02B$14.84B
Inventory$15.38B$15.14B$14.58B$14.19B$14.15B$13.41B$12.66B$12.44B
Current assets$56.35B$59.77B$59.17B$55.62B$54.61B$54.50B$71.55B$55.89B
PP&E, net$24.10B$23.58B$23.27B$23.17B$22.34B$21.95B$20.87B$20.52B
Goodwill$48.47B$48.48B$48.56B$48.77B$48.05B$48.12B$44.47B$44.20B
Intangibles$46.65B$48.23B$49.06B$50.40B$48.74B$49.84B$36.76B$37.62B
Total assets$197.43B$201.06B$200.89B$199.21B$192.82B$193.39B$193.67B$180.10B
Current liabilities$55.46B$54.90B$57.72B$54.13B$50.87B$54.18B$56.90B$50.32B
Short-term debt$8.85B$11.69B$17.46B$8.49B$6.39B$11.53B$13.90B$6.00B
Long-term debt$35.80B$37.34B$37.53B$39.44B$39.41B$39.23B$38.35B$30.65B
Total debt$44.65B$49.04B$54.99B$47.93B$45.80B$50.76B$52.25B$36.65B
Total liabilities$115.90B$116.09B$119.71B$117.67B$113.54B$114.92B$115.56B$108.61B
Shareholders' equity$81.53B$84.97B$81.19B$81.54B$79.28B$78.47B$78.11B$71.49B
Net debt$27.74B$28.61B$33.30B$28.22B$27.56B$32.18B$13.78B$12.55B
Cash flow statement
Operating cash flow$7.72B$8.62B$2.51B$7.31B$9.17B$3.88B$4.17B$6.98B
Capital expenditure$1.36B$1.32B$1.05B$1.84B$1.16B$1.04B$795.00M$1.61B
Free cash flow$6.36B$7.29B$1.47B$5.47B$8.01B$2.83B$3.38B$5.37B
Investing cash flow-$2.71B-$1.11B-$1.04B-$4.49B-$542.00M-$18.26B-$297.00M-$1.32B
Financing cash flow-$8.53B-$8.78B$530.00M-$1.37B-$8.93B-$5.67B$10.42B-$1.34B
Depreciation & amortization$2.12B$1.96B$2.00B$2.01B$1.78B$1.94B$1.77B$1.90B
Stock-based compensation$357.00M$458.00M$300.00M$309.00M$347.00M$410.00M$288.00M$238.00M
Share buybacks$1.71B$221.00M$4.03B$1.92B$1.90B$0$2.13B$282.00M

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.